Skip to main content

Evidence to Improve Care

Noninvasive Fetal RhD Blood Group Genotyping

Draft Recommendation

The Quality business unit at Ontario Health, based on guidance from the Ontario Health Technology Advisory Committee, recommends publicly funding noninvasive fetal RhD blood group genotyping for:

  • Alloimmunized RhD negative pregnancies

  • Nonalloimmunized RhD negative pregnancies conditional on attaining reasonable cost-effectiveness in the future

Read the draft recommendation report

We want to hear from you.

This topic is now available for public feedback until January 26, 2020. Please feel free to forward this page to any individual you think may be interested in reviewing this assessment. All comments will be considered before a final recommendation is made and posted here.

Use the tabs below to learn more about this topic, download supporting draft documents, including the full assessment report, and submit feedback.

To be notified once a final recommendation is posted here, sign up for our newsletter.


Rhesus (Rh) factor (also called D-antigen) is an inherited protein found on red blood cells. If a person’s blood has the protein, they’re RhD positive. If not, they’re RhD negative. Normally, this doesn’t affect a person’s health, but it may cause complications during pregnancy if the pregnant person and fetus have incompatible blood types.

Currently, as a precaution, all pregnant people with RhD negative blood types receive an injection to prevent their immune system from developing antibodies that fight against their fetus’s blood type. If antibodies do develop, they don’t pose a risk to the first pregnancy, but future pregnancies are closely monitored. These steps aren’t necessary in pregnancies without RhD incompatibility. A blood test called noninvasive fetal RhD blood group genotyping (RhD genotyping) can look at fetal DNA in the pregnant person’s blood and see if the pregnancy is RhD incompatible.

This health technology assessment looked at how accurate, clinically useful, and cost-effective this genotyping test is for determining if a pregnancy is RhD incompatible to help guide care. It also looked at the budget impact of publicly funding the test and at the experiences, preferences, and values of patients and health care providers related to care for RhD incompatible pregnancies.

Read the full health technology assessment report for more information.

Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment (PDF)
January 2020

Use of this site, and the interpretation of the information contained here, is subject to important terms and conditions. Use of this site and information except in accordance with these terms and conditions is expressly prohibited.

We reviewed evidence on the use of noninvasive fetal RhD blood group genotyping. Read the latest draft recommendation and share your feedback.

Submit Feedback


Date posted: January 6, 2020
Closing date for public comment: January 26, 2020




RECEIVE NOTIFICATION OF WHEN OUR DRAFT RECOMMENDATIONS ARE OPEN FOR FEEDBACK

Sign up for our newsletter to receive monthly notifications of when draft recommendations are open for feedback

A senior couple looking at their tablet together

Let’s make our health system healthier

Join Our Patient, Family and Public Advisors Program

Patients, families and the public are central to improving health quality.


Man smiling

Sign up for our newsletter

Are you passionate about quality health care for all Ontarians? Stay in-the-know about our newest programs, reports and news.

Health Quality Connect - Health Quality Ontario's newsletter - on an iPad and a cell phone